Results 131 to 140 of about 316,835 (263)

Bayesian model averaging for partial ordering continual reassessment methods. [PDF]

Biostatistics
Kovačević L, Chen W, Barnett H, Jaki T, Mozgunov P.   +4 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Bayesian Model Averaging of Parametric Coalescent Models for Phylodynamic Inference. [PDF]

Mol Biol Evol
Xu Y, Chen K, Xie D, Drummond AJ.
europepmc   +1 more source

Exercise is the dominant factor affecting the development of teenagers' eyesight-Based on the Bayesian model averaging. [PDF]

Front Public Health, 2022
Liu ZH, Zhao MF, Ma S, Li Y, Sun ZY, Gao L.   +5 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods. [PDF]

Clin Pharmacokinet
Le Louedec F, Morvan L, Mourey L, Maillard M, Vachoux C, Yakoubi M, Tosi D, Gravis G, Roubaud G, Thuillier F, Boyle H, Thomas F, White-Koning M, Puisset F, Chatelut É.   +14 more
europepmc   +1 more source

Rank-Based Greedy Model Averaging for High-Dimensional Survival Data. [PDF]

J Am Stat Assoc, 2023
He B, Ma S, Zhang X, Zhu LX.
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Robust Bayesian Model Averaging Meta-Analysis of Menstrual Disorders in COVID-19 Survivors: A Methodological Meta-Analysis Study. [PDF]

Health Sci Rep
Falahati G, Biglarian A, Behboudi-Gandevani S, Bidhendi-Yarandi R.   +3 more
europepmc   +1 more source

Estimation for volunteer web survey samples using a model-averaging approach. [PDF]

J Appl Stat, 2023
Liu Z, Zheng J, Tu C, Pan Y.
europepmc   +1 more source